<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054236</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU6Y01</org_study_id>
    <nct_id>NCT00054236</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia</brief_title>
  <official_title>Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Umbilical cord blood transplantation may be able to replace&#xD;
      cells destroyed by chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy followed by&#xD;
      umbilical cord blood transplantation in treating patients who have hematologic cancer or&#xD;
      severe aplastic anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the incidence and severity of acute toxicity in patients with hematologic&#xD;
           malignancies or severe aplastic anemia treated with a non-myeloablative conditioning&#xD;
           regimen followed by umbilical cord blood transplantation.&#xD;
&#xD;
        -  Determine the incidence and severity of acute and chronic graft-versus-host-disease in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of relapse, disease-free survival, and overall survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the survival rate at 100 days post-transplantation in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the incidence of regimen-related complications (infection, hepatic&#xD;
           veno-occlusive disease, and interstitial pneumonitis) in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the incidence of primary and secondary graft failure in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the rates and kinetics of donor-derived lymphoid, myeloid, neutrophil, RBC,&#xD;
           and platelet engraftment in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive a non-myeloablative conditioning regimen comprising fludarabine IV&#xD;
      over 30 minutes on days -8 to -4, cyclophosphamide IV over 2 hours on days -3 to -2, and&#xD;
      anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1. Patients unable to&#xD;
      tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.&#xD;
&#xD;
      Patients undergo multiple unit umbilical cord blood transplantation on days 0-1. Patients&#xD;
      receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood&#xD;
      counts recover.&#xD;
&#xD;
      Patients are followed monthly for 6 months; at 9, 12, 14, 16, 18, and 24 months; and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival by disease assessment</measure>
    <time_frame>at 28 and 100 days and then at 6, 9, 12, 18, and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC)</measure>
    <time_frame>monthly for 6 months and then at 9, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <arm_group>
    <arm_group_label>non-myeloablative conditioning regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1</description>
    <arm_group_label>non-myeloablative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.</description>
    <arm_group_label>non-myeloablative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide IV over 2 hours on days -3 to -2</description>
    <arm_group_label>non-myeloablative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>fludarabine IV over 30 minutes on days -8 to -4</description>
    <arm_group_label>non-myeloablative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.</description>
    <arm_group_label>non-myeloablative conditioning regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.</description>
    <arm_group_label>non-myeloablative conditioning regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following histologically confirmed diagnoses:&#xD;
&#xD;
               -  Acquired severe aplastic anemia&#xD;
&#xD;
                    -  Meets at least 2 of the following criteria:&#xD;
&#xD;
                         -  Granulocyte count less than 500/mm^3&#xD;
&#xD;
                         -  Platelet count less than 20,000/mm^3&#xD;
&#xD;
                         -  Absolute reticulocyte count less than 20,000/mm^3 (after correction for&#xD;
                            hematocrit)&#xD;
&#xD;
                    -  Unresponsive to OR recurrent disease after prior treatment with&#xD;
                       anti-thymocyte globulin and/or cyclosporine&#xD;
&#xD;
               -  Acute myeloid leukemia (AML), meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Failed induction therapy&#xD;
&#xD;
                    -  In first complete remission (CR) with any of the following high-risk&#xD;
                       features:&#xD;
&#xD;
                         -  Stem cell or biphenotype classification (M0)&#xD;
&#xD;
                         -  Erythroleukemia (M6)&#xD;
&#xD;
                         -  Acute megakaryocytic leukemia (M7)&#xD;
&#xD;
                         -  Cytogenetic markers indicative of poor prognosis&#xD;
&#xD;
                         -  t(15;17) translocation and failed first-line induction therapy OR there&#xD;
                            is molecular evidence of persistent disease&#xD;
&#xD;
                         -  t(8;21) and inv(16) translocations and failed first-line induction&#xD;
                            therapy&#xD;
&#xD;
                    -  In early relapse*&#xD;
&#xD;
                    -  In second or subsequent remission&#xD;
&#xD;
                    -  Recurrent disease after prior autologous stem cell transplantation (SCT)&#xD;
                       NOTE: *No refractory relapse&#xD;
&#xD;
               -  Acute lymphoblastic leukemia, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In early relapse*&#xD;
&#xD;
                    -  In second or subsequent remission&#xD;
&#xD;
                    -  In first CR with the following high-risk features:&#xD;
&#xD;
                         -  t(4;11) or t(9;22) translocation&#xD;
&#xD;
                         -  Hyperleukocytosis (initial WBC greater than 30,000/mm^3)&#xD;
&#xD;
                         -  Failed to achieve CR by day 28 of standard induction therapy&#xD;
&#xD;
                    -  Recurrent disease after prior autologous SCT NOTE: *No refractory relapse&#xD;
&#xD;
               -  Chronic myelogenous leukemia&#xD;
&#xD;
                    -  Chronic or accelerated phase that has failed medical management&#xD;
&#xD;
                    -  Blastic phase allowed after reinduction chemotherapy induces chronic phase&#xD;
&#xD;
               -  Myelodysplastic syndromes meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Refractory to medical management&#xD;
&#xD;
                    -  Presence of cytogenetic abnormalities predictive of transformation to acute&#xD;
                       leukemia, including the following:&#xD;
&#xD;
        = 5q- = 7q-&#xD;
&#xD;
          -  Monosomy 7 and trisomy 8&#xD;
&#xD;
          -  Evidence of evolution to AML (e.g., refractory anemia with excess blasts [RAEB], or&#xD;
             RAEB in transformation)&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Refractory to treatment including fludarabine-based therapy&#xD;
&#xD;
                    -  Recurrent disease after prior autologous SCT&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
                    -  Recurrent disease after prior autologous SCT&#xD;
&#xD;
                    -  Beyond first CR or failed induction therapy&#xD;
&#xD;
                    -  Disease is sensitive to pretransplantation cytoreduction&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
                    -  Beyond first CR or failed induction therapy&#xD;
&#xD;
                    -  Disease is sensitive to pretransplantation cytoreduction&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
                    -  Recurrent disease after prior autologous SCT&#xD;
&#xD;
                    -  Beyond first CR or failed induction therapy&#xD;
&#xD;
                    -  Disease is sensitive to pretransplantation cytoreduction&#xD;
&#xD;
                    -  Mantle zone NHL allowed after induction therapy&#xD;
&#xD;
               -  Myeloproliferative disorders&#xD;
&#xD;
                    -  Refractory to medical management&#xD;
&#xD;
                    -  Allografting required unless grade 3 or greater myelofibrosis by bone marrow&#xD;
                       biopsy&#xD;
&#xD;
                         -  No HLA-matched sibling donor available&#xD;
&#xD;
                         -  Ineligible for a myeloablative conditioning regimen due to advanced age&#xD;
                            (over 55), extensive prior therapy, and/or other comorbidities&#xD;
&#xD;
                         -  If under age 55, must meet at least 1 of the following criteria:&#xD;
&#xD;
               -  Received extensive prior therapy&#xD;
&#xD;
               -  Organ toxicity or infection precluding eligibility for allogeneic transplantation&#xD;
                  with full ablation conditioning&#xD;
&#xD;
                    -  Availability of 2-5 umbilical cord blood units that are at least a 4/6 HLA&#xD;
                       match&#xD;
&#xD;
                    -  No active CNS disease&#xD;
&#xD;
                    -  No primary or grade 3 or 4 myelofibrosis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100% (for patients 16 years of age and older)&#xD;
&#xD;
          -  Lansky 50-100% (for patients under 16 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT/AST less than 4 times normal&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL (unless due to hepatic infiltration by primary&#xD;
             malignancy)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance greater than 40 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Shortening fraction or ejection fraction greater than 40% of normal value for age by&#xD;
             echocardiogram or radionuclide scan&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FVC and FEV_1 greater than 60% of predicted&#xD;
&#xD;
          -  DLCO greater than 60% of predicted (adult patients)&#xD;
&#xD;
          -  Clearance by pulmonologist required if patient cannot perform pulmonary function tests&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No uncontrolled active infection (viral, bacterial, or fungal)&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 months since prior autologous stem cell transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No other concurrent investigational agents that would preclude study participation or&#xD;
             increase risk to patient&#xD;
&#xD;
               -  Investigational diagnostic procedures allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Cooper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>childhood acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

